These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 25333206

  • 1. Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
    Lin CL, Chiang WF, Tung CL, Hsieh JL, Hsiao JR, Huang WT, Feng LY, Chang CH, Liu SY, Tsao CJ, Feng YH.
    Mol Med Rep; 2015 Jan; 11(1):547-54. PubMed ID: 25333206
    [Abstract] [Full Text] [Related]

  • 2. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C, Lu W, Ren Z, Tang Y, Zhang C, Yang R, Chen Y, Cao W, Wang L, Wang X, Ji T.
    Cancer Lett; 2016 Jul 10; 377(1):1-10. PubMed ID: 27090738
    [Abstract] [Full Text] [Related]

  • 3. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
    Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S.
    Clin Cancer Res; 2015 Oct 01; 21(19):4356-64. PubMed ID: 26015511
    [Abstract] [Full Text] [Related]

  • 4. Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation.
    Chang JW, Jung SN, Kim JH, Shim GA, Park HS, Liu L, Kim JM, Park J, Koo BS.
    Sci Rep; 2016 Jun 22; 6():28503. PubMed ID: 27328758
    [Abstract] [Full Text] [Related]

  • 5. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA, Arroyo-Solera I, Téllez-Gabriel M, León X, Virós D, López M, Gallardo A, Céspedes MV, Casanova I, López-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R.
    Oncotarget; 2015 Oct 06; 6(30):29016-33. PubMed ID: 26359694
    [Abstract] [Full Text] [Related]

  • 6. Knockdown of HPIP Inhibits the Proliferation and Invasion of Head-and-Neck Squamous Cell Carcinoma Cells by Regulating PI3K/Akt Signaling Pathway.
    Chen Y, Zhao R, Zhao Q, Shao Y, Zhang S.
    Oncol Res; 2016 Oct 06; 24(3):153-60. PubMed ID: 27458096
    [Abstract] [Full Text] [Related]

  • 7. Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.
    Ma SR, Deng WW, Liu JF, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ.
    Mol Cancer; 2017 Jun 07; 16(1):99. PubMed ID: 28592285
    [Abstract] [Full Text] [Related]

  • 8. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
    Bhatt VR, Ganti AK.
    Future Oncol; 2014 Jan 06; 10(1):17-20. PubMed ID: 24328406
    [No Abstract] [Full Text] [Related]

  • 10. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, Joyce S, Lui VW, Zeng Y, Chiosea SI, Grandis JR.
    Neoplasia; 2015 Mar 06; 17(3):256-64. PubMed ID: 25810010
    [Abstract] [Full Text] [Related]

  • 11. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
    Affolter A, Samosny G, Heimes AS, Schneider J, Weichert W, Stenzinger A, Sommer K, Jensen A, Mayer A, Brenner W, Mann WJ, Brieger J.
    Head Neck; 2017 Apr 06; 39(4):623-632. PubMed ID: 28221700
    [Abstract] [Full Text] [Related]

  • 12. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM.
    Cancer Lett; 2017 Apr 28; 392():71-82. PubMed ID: 28126323
    [Abstract] [Full Text] [Related]

  • 13. RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma.
    Tumur Z, Katebzadeh S, Guerra C, Bhushan L, Alkam T, Henson BS.
    Neoplasia; 2015 Jan 28; 17(1):141-51. PubMed ID: 25622907
    [Abstract] [Full Text] [Related]

  • 14. MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
    Liu F, Zhao X, Qian Y, Zhang J, Zhang Y, Yin R.
    Biomed Pharmacother; 2017 Dec 28; 96():229-237. PubMed ID: 28987947
    [Abstract] [Full Text] [Related]

  • 15. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 28; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 16. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C, Faber A, Umbreit C, Birk R, Weiss C, Sommer JU, Hörmann K, Schultz JD.
    Anticancer Res; 2015 Apr 28; 35(4):1951-9. PubMed ID: 25862847
    [Abstract] [Full Text] [Related]

  • 17. Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck.
    Pickhard A, Gröber S, Haug AK, Piontek G, Wirth M, Straßen U, Rudelius M, Reiter R.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Jun 28; 117(6):733-42. PubMed ID: 24726415
    [Abstract] [Full Text] [Related]

  • 18. Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.
    Liu CJ, Chang WJ, Chen CY, Sun FJ, Cheng HW, Chen TY, Lin SC, Li WC.
    Oncotarget; 2015 Oct 06; 6(30):29268-84. PubMed ID: 26337468
    [Abstract] [Full Text] [Related]

  • 19. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z, Li H, Huang Q, Chen D, Han J, Wang L, Pan C, Chen W, House MG, Nephew KP, Guo Z.
    Mol Carcinog; 2014 Oct 06; 53(10):777-86. PubMed ID: 23661500
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
    Stanam A, Gibson-Corley KN, Love-Homan L, Ihejirika N, Simons AL.
    Oncotarget; 2016 Nov 15; 7(46):76087-76100. PubMed ID: 27738319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.